Clinical review: impact of statin substitution policies on patient outcomes. - Wikidata - wikimedia - TriplyDB

Clinical review: impact of statin substitution policies on patient outcomes.

Clinical review: impact of statin substitution policies on patient outcomes.

http://www.wikidata.org/entity/Q37384820

about

Off-patent generic medicines vs. off-patent brand medicines for six reference drugs: a retrospective claims data study from five local healthcare units in the Lombardy Region of Italy.Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US.Implementing a statin switching programme in primary care: patients' views and experiences.Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.Clinical Implications of Switching Lipid Lowering Treatment from Rosuvastatin to Other Agents in Primary Care.Therapy discontinuation or substitution in patients with cardiovascular disease, switching among different products of the same off-patent active substance: a 'real-world' retrospective cohort study.Lipid-lowering treatment modifications among patients with hyperlipidemia and a prior cardiovascular event: a US retrospective cohort study.To switch (statins) or not to switch? That is the question.Impact of out-of-pocket expenses on discontinuation of statin therapy: a cohort study in Finland.

P2860

Q30724115-D60462E3-2E49-4A07-8F76-FB774915B434 Q33559274-DDC49811-1DF6-460D-BBBD-7889064FE45F Q36087995-3FB9210F-0A05-4E4D-B191-7D08DF221675 Q37324420-10B727AC-18F8-4FE0-AB04-BB435621E4A8 Q37373193-A0BE9613-B851-4458-80C6-B1B48F44F803 Q37454789-80B309E4-2C8C-4A88-A5D6-719A1741EC19 Q38918971-939C5CBB-0AF4-4732-A1A5-91F081596397 Q42854439-D9341C5D-0E2B-4A63-9BBA-F168A2D22B1F Q44871003-8F508510-4886-43CF-9D57-9DD4F30922F2

P2860

Clinical review: impact of statin substitution policies on patient outcomes.

http://www.wikidata.org/entity/Q37384820

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Clinical review: impact of statin substitution policies on patient outcomes.

@en

Clinical review: impact of statin substitution policies on patient outcomes.

@nl

type

label

Clinical review: impact of statin substitution policies on patient outcomes.

@en

Clinical review: impact of statin substitution policies on patient outcomes.

@nl

prefLabel

Clinical review: impact of statin substitution policies on patient outcomes.

@en

Clinical review: impact of statin substitution policies on patient outcomes.

@nl

P1433

Q37384820-0741CACD-5F54-4779-BDCC-13519B0551DB

P1476

Q37384820-8E46F08E-D7AE-49AD-99B1-F43AB69994CF

P2093

Q37384820-200F11E8-F68E-4CA7-81B9-D964E8DAE563

Q37384820-47AC981E-FADE-4230-B58F-6FA4DC7B17EC

Q37384820-622F4B0F-9356-4183-9DAE-A737F9C9138A

Q37384820-657BEB9C-C79F-4F5A-8901-5026EDB56108

Q37384820-A6AC1905-5E21-4356-8A30-BED931447986

Q37384820-B973B73F-D14C-4DF4-BFF7-3FEB6037E725

P2860

Q37384820-01BC7326-8B9C-457C-8D0A-0DCDAB818F6D

Q37384820-06230821-C075-4EF7-8C77-E1A29B6FEDD7

Q37384820-0D773340-6B07-4B97-A523-B6974277CBC9

Q37384820-103559CA-BDB4-4E70-ACF5-6830F924D3FF

Q37384820-24A35384-1C1D-461D-9F77-2602F93CC51D

Q37384820-2F17C2B8-5714-4E9F-BE52-ADEC55E12FAE

Q37384820-317793D4-73D3-45CE-B0E2-E20AC3F48B4E

Q37384820-36A19C16-8611-44AA-AC5D-2336C2B15FE6

Q37384820-39C7D3CB-74F0-4F22-973B-F0115B35F852

Q37384820-3C6A26D8-D1BA-4A60-BC9A-335F94372B89

P304

Q37384820-F373F85D-9E7F-4D23-8E05-FD96638A611B

P31

Q37384820-6270755D-9E10-4D1D-A298-0B5BBD75C9CE

P356

Q37384820-F8876E79-114A-41FE-B289-2988DDC4DDE7

P407

Q37384820-BE499164-021D-4CAD-BCAA-EFBB69796546

P433

Q37384820-E62E6E1A-AF23-4559-BDC3-CDD34347C67C

P478

Q37384820-49446A8F-958E-4190-BD34-E51C3527C61C

P50

Q37384820-3B3F56C8-4CA4-417F-9BC6-B3F9204B4274

P577

Q37384820-92EAD3B4-C44C-4B07-BA52-099888D7C4FF

P698

Q37384820-17451C71-8FE1-445F-A51E-06E072C4FEA3

P921

Q37384820-09BF4191-EC44-47FC-9121-76E18402799E

P356

07853890902729786

P1433

Annals of Medicine

P1476

Clinical review: impact of statin substitution policies on patient outcomes.

@en

P2093

Annik K-Laflamme

http://www.w3.org/2001/XMLSchema#string

Peter Clemmensen

http://www.w3.org/2001/XMLSchema#string

Peter Lansberg

http://www.w3.org/2001/XMLSchema#string

Rafael Carmena

http://www.w3.org/2001/XMLSchema#string

Richard Hobbs

http://www.w3.org/2001/XMLSchema#string

Sven Wassmann

http://www.w3.org/2001/XMLSchema#string

P2860

European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constitute

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

Implications of cardiac risk and low-density lipoprotein cholesterol distributions in the United States for the diagnosis and treatment of dyslipidemia: data from National Health and Nutrition Examination Survey 1999 to 2002.

Statin cost-effectiveness comparisons using real-world effectiveness data: formulary implications.

Are drugs within a class interchangeable?

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.

Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology.

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

P304

242-256

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/07853890902729786

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

41

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19191052

http://www.w3.org/2001/XMLSchema#string

P921